Novo Integrated Sciences Appoints Dr. Indrajit (Indra) Sinha Ph.D. as Chief Science Officer
Retrieved on:
Wednesday, July 7, 2021
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the Company or Novo) announces that Dr. Indrajit Indra Sinha, Ph.D. has been appointed as Novos Chief Science Officer, effective June 24, 2021.
Key Points:
- Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the Company or Novo) announces that Dr. Indrajit Indra Sinha, Ph.D. has been appointed as Novos Chief Science Officer, effective June 24, 2021.
- Dr. Sinha brings over 25 years of experience in various areas of cross-disciplinary translational research, drug development, biotechnology, technology transfer, and biopharmaceutical compliance.
- Dr. Sinha commented, Novo has a clear focus and vision of how to expand its personalized consumer engagement across all aspects of the patient/practitioner relationship.
- Innovation in science as represented by the proprietary technology assures Novo of continued cutting edge advancement in patient first platforms.